Nonpatentable drugs and the cost of our ignorance

Calon, Frédéric
February 2006
CMAJ: Canadian Medical Association Journal;2/14/2006, Vol. 174 Issue 4, p483
Academic Journal
The article comments on the issue of funding for the pharmaceutical industry's randomized controlled clinical trials (RCT). Potential efficacy of drugs based on patentability and nonpatentability is questioned. The viability of investing in the clinical study for nonpatented drugs is also discussed.


Related Articles

  • PhRMA updates principles for conduct of clinical trials.  // Pharmacy Today;Aug2004, Vol. 10 Issue 8, p3 

    The Pharmaceutical Research and Manufacturers of America (PhRMA) has adopted a set of updated principles for conducting and reporting clinical trials that commit drug companies to the timely communication of all meaningful results, whether those results are positive or negative. PhRMA stated...

  • Site relationship management: Sponsors help sites be more productive.  // Clinical Trials Administrator;Jul2008, Vol. 6 Issue 7, p73 

    The article looks at the site relationship management (SRM) and investigator relationship management (IRM) initiatives by pharmaceutical companies to improve relationships with clinical trial sites. It mentions some of the common goals of trial sponsors including helping sites function better...

  • Clinical Trials and CROs in the 21st Century. Hindin, Toby Jane // Applied Clinical Trials;Jun2004, Vol. 13 Issue 6, p12 

    The clinical research oversight (CRO) industry has reached a new stage of growth in clinical trials. There are now more than one thousand CRO with the largest number existing in Europe, followed by North America and Japan. While research and development costs are skyrocketing, product approvals...

  • Opexa reports additional positive data from Phase IIb multiple sclerosis study.  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p9 

    The article reports on additional positive results from Opexa Therapeutics Inc.'s Phase IIb clinical trial for Tovaxin for the treatment of multiple sclerosis. The findings indicate that Tovaxin demonstrated a benefit across all clinical and magnetic resonance imaging endpoints in prospective...

  • Strategic Approach Needed for International Clinical Trials. Abuchowski, Abraham; Kazo, Glenn // Applied Clinical Trials;Aug/Sep2014, Vol. 23 Issue 8/9, p42 

    The article reports on the aspects of clinical trials in the pharmaceutical industries. It states that clinical trials are important for drug's approval and as basis for the evidence of efficacy and safety. Also mentioned that clinical trials are affected by several factors such as the...

  • Avexa Shares Jump 45% on Apricitabine HIV Data.  // Bioworld Week;3/23/2009, Vol. 17 Issue 12, p3 

    The article reports on the increased in Avexa Ltd. shares following a positive Phase IIb clinical trial data for its HIV drug apricitabine (ATC). According to reports, the company's shares gained A3 cents to close at A10 cents. The company reported 96-week data that provides evidence for ATC's...

  • A New Colonialism? – Conducting Clinical Trials in India. Nundy, Samiran; Gulhati, Chandra M. // New England Journal of Medicine;4/21/2005, Vol. 352 Issue 16, p1633 

    The article reports that the government of India in January 2005 rendered a new rule which allows foreign pharmaceutical companies to conduct trials of new drugs in India at the same time that trials of the same phase are being conducted in other countries. This new rule replaces the directive...

  • Waxman scolds PhRMA firms for ignoring patient resource. Dickinson, James G. // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p17 

    Reports on the complaint issued by U.S. Rep. Henry Waxman to the Pharmaceutical Research and Manufacturers of America about the failure of companies to report their cancer clinical trials, as required by law. Failure of the pharmaceutical industry to report trials on a web site as required;...

  • Long-term assessment of drug safety and efficacy. Turner, Paul // Journal of the Royal Society of Medicine;Feb1984, Vol. 77 Issue 2, p93 

    The author reflects on the assessment of drug safety and efficacy. He says that the safety and efficacy of a drug cannot be accurately assessed from short-term clinical trials in tens or hundreds of patients. He concludes that there is no alternative to long-term controlled therapeutic trials to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics